



Peijia Medical

2023 Annual Results

June 17, 2024



Disclaimer



- The documents, opinions and materials presented in this presentation (the “Document”) have been prepared by Peijia Medical Limited (the “Company”) for use in presentations by the Company and does not constitute a recommendation regarding the securities of the Company. You fully understand that the Document is being made available on a confidential basis and subject to the following provisions. The contents of this Document have not been reviewed by any regulatory authority in any jurisdiction. The distribution of this Document in certain jurisdictions may be restricted by law, and the recipients into whose possession this Document comes should inform themselves about, and observe such restrictions. By accessing this Document, you are agreeing (i) that you have read and agree to comply with the contents of this notice and disclaimer and (ii) to maintain absolute confidentiality regarding the information disclosed in this Document.
- This Document has not been independently verified and is not intended to form the basis of any investment decision. It does not constitute an offer or invitation to sell, or any solicitation of any offer to subscribe for or purchase any securities in any jurisdiction in which the making of such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction or would not otherwise be in compliance with the laws and regulations of such jurisdiction, and nothing contained herein shall form the basis of any investment decision, contract or commitment whatsoever. This Document contains no information or material which may result in it being deemed (1) to be an advertisement, invitation or document containing an advertisement or invitation falling within the meaning of section 103 of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “Securities and Futures Ordinance”) or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.
- The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under the laws of any state of the United States. This Document does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States and is not for distribution and may not be distributed, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). The securities of the Company will not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to the registration requirements of the U.S. Securities Act. There will be no public offer of the Company’s securities in the United States.
- This Document and the information contained herein as well as information presented orally or otherwise are strictly confidential and must be treated as such. Neither the information contained in this Document nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, PRC, Hong Kong or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other jurisdiction’s securities laws. Upon request, the recipient will promptly return this Document and any other written information made available in the presentation, without retaining any copies.
- This Document does not purport to be comprehensive or to contain all the information that a recipient may need in order to evaluate the Group. No representation, warranty or undertaking, express or implied, is given and, so far as is permitted by law, no responsibility or liability is accepted by any person (for the avoidance of doubt, including but not limited to, the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing), with respect to the accuracy, reliability, correctness, fairness or completeness of this Document or its contents. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as “will”, “expects”, “intends”, “plans to” and “anticipates” and words of similar import. These forward-looking statements reflects the current view of the Company with respect to future events are based on a number of assumptions about the Company’s procedures and factors beyond the Company’s control and are subject to significant risks and uncertainties, and, accordingly, actual results may differ materially from these forward-looking statements. In particular, but without limitation, no representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any assumptions, projections, targets, estimates, forecasts or any forward-looking statements contained in this Document. Each of the Company and its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing assumes no obligation to update or otherwise revise these forward-looking statements for new information, events or circumstances that occur subsequent to such dates. None of the Company and any of its affiliates, controlling persons, directors, officers, partners, employees, agents, representatives or advisers of any of the foregoing shall have any liability (in negligence or otherwise) in respect of the use of, or reliance upon, the information contained herein by you or any person to whom the information herein is disclosed.
- In furnishing this Document, the Company and its affiliates undertake no obligation to provide any additional information or to update this Document or any additional information or to correct any inaccuracies which may become apparent.

Contents

01

**Business
Highlights**

02

**Transcatheter
Valve
Therapeutic
Business
Review**

03

**Neuro
interventional
Business
Review**

04

**Financial
Review**

05

Appendix

Contents

01

**Business
Highlights**

02

Transcatheter
Valve
Therapeutic
Business
Review

03

Neuro
interventional
Business
Review

04

Financial
Review

05

Appendix

2023 Annual Business Highlights



01/ Revenue scaled up rapidly with impressive growth rate

- 2,484 TAVR products were implanted in 2023, which is more than double the implantation volume in 2022, driving more than 20% Chinese transfemoral TAVR market share⁽¹⁾;
- Better-than-expected revenue growth of nearly 80% was seen in NI Business driven by domestic replacement and new products/techniques.

02/ Gross margin steadily improved, building foundation for long-term competition

- Gross margin of TVT Business increased 6.0% YoY to 85.7% driven by supply chain optimization and yield rate improvement;
- Gross margin of NI Business maintained stable around 70% as a result of effective cost control measures.

03/ Operational efficiency improved and NI segment loss narrowed to RMB744k

- TVT Business S&D, Administrative and R&D expense ratios dropped 32.5%, 25.9% and 169.5% YoY, respectively, as the emergence of economic scales;
- NI Business S&D, Administrative and R&D expense ratios further went down by 14.2%, 9.9% and 15.7% YoY, respectively, driving segment losses to only RMB744K.

04/ Registration clinical trials were accelerated

- We expedited the registration clinical trials during the year and have completed the patient enrollment of the registration clinical trial for TaurusNXT[®] and TaurusTrio[™] and GeminiOne[®].
- Specially, we enrolled a total of 116 AR patients within 6 months in TaurusTrio[™] trial ahead of schedule, breaking our clinical record.

An Excellent 4 Years of Development

125% ↑



Group Revenue CAGR

88% ↑

NI Revenue CAGR

Million RMB

Million RMB




+20% ↑


TAVR Market Share

¥ 0.7M


NI segment loss



Million RMB



TVT Business Pipeline



source: (1) Annual Report, Structural heart disease annual report 2021 from National Quality Control Center, Structural heart disease annual report 2022 and 2023, Sales Estimates

Three Years into TAVR Commercialization

¥ 185.6M

2023 Revenue

*CAGR 110.5%
(2021 – 2023)*


YOY +4.4% ↑
20.2%
2023
transfemoral
TAVR market

YOY +6.0% ↑
85.7%
GP Margin

Implantation Volume

2023 **2,484**


YoY Growth **106%**



Hospital Coverage

As of 2023 **489**


2023 New **+199**



Sales and Marketing Team

As of 2023 **200**


2023 New **+15**



Distribution Network

As of 2023 **260**


2023 New **+82**



Controlled Rate of Cash Consumption and Positive Cash Flow Trends


Cash, Cash Equivalents and Term Deposits

Million RMB



Net Cash Used in Operating Activities

Million RMB



TVT R&D
Expense ratio
169.5 pct


TVT S&D
Expense ratio
32.5 pct

2023 NI
segment loss
¥ 0.7M

Leverage rate
against revenue
50%


TVT R&D Expenses

Million RMB




Achieva Gain/Loss

Million RMB




TVT S&D Expenses

Million RMB



Revenue & Leverage

Million RMB



Business Updates

01 Volume of the Company's TAVR products is increasing.

- Average implantation volume 300+ per month
- Over 550 hospitals

02 Iterations are coming out.

- Gradual commercialization of smaller sized flaps, 1.5 generation and 2.5 generation
- Improve product performance and establish a product price ladder

03 Enrollment in clinical trials is accelerating.

- Patient enrollment of registration clinical trials for TaurusTrio™, TaurusNXT® and GeminiOne® has completed, leading

04 NI Business is growing.

- Revenue is still growing at a high rate even after the implementation of VBPs.
- Firming the segment's goal of achieving profitability.



The market is split into three, and the momentum of the company is very strong.

- TAVR market share is steadily increasing.
- Hospital coverage is on par with peers.

■ Pipelines are abundant.

- Iteration
- A whole new field



"Strongest" Pipeline



Contributions of NI business

- Cash Flow
- Top companies benefit from VBPs
- Advantages of Platform-based Enterprises Emerge

Contents

01

Business
Highlights

02

**Transcatheter
Valve
Therapeutic
Business
Review**

03

Neuro
interventional
Business
Review


04

Financial
Review

05

Appendix

Growth Curve of TVT Business



Implantation Volume and Market Share


Market Update

Implantation Volume



Estimated Peijia Market Share⁽¹⁾


23.7%	20.2%	16.6%	FY23
16.6%	15.8%	13.9%	FY22



source: (1) Annual Report, 2022, 2023 Structural Heart Report, Sales Estimates

Implantation Volume Distribution

Peijia implantation distribution across all hospital tiers has converged on market distribution.



Note: TOP/KA/STAR/Beginner hospitals are categorized based on actual or estimated single hospital procedure volume for each year.
Source: Management estimates.

Financial Overview | TVT Business

Revenue constantly grew at high-double digits and gross profit margin maintained the highest among peers.


Revenue

Million RMB




Gross Profit and Gross Margin

Million RMB




Expenses

Million RMB






Segment Losses

Million RMB



Financial Overview | TVT Business

Trends in expenses and expense ratios



- Personnel salary accounted for the main part, the company built commercialization team in advance, and now has sufficient scale. Expense growth will slow down as HC will maintain organic growth in the future.
- Other expenses stabilized and were manageable;
- Per capita implantation volume improved significantly, diluting base expenses;
- Further apportionment of base expenses will be made when the product is launched.











- The external BD payment is nearing completion with a remaining milestone payment due not exceed RMB300 million, of which approximately \$50 million will be charged to R&D expenses;
- The clinical registration of three core products has been completed in 2024. The subsequent clinical expenses will be gradually reduced and under control.

- Administrative expenses was stable and grew at a flat rate;
- The administrative expense ratio has decreased year by year.

Note: (1)Per capita implantation volume=Implantation/Average number of sales, where the average number of sales refers to the number of pure sales, excluding commercial staff.

Pipeline Update

Accelerated registration clinical trials, establishing product portfolio for long-term competition.

Aortic Valve	Aortic Regurgitation	Aortic Stenosis					
	TaurusTrio™   Launched in HK Completed Patient Enrollment of Registration Clinical Trial  JenaValve	Implant		Non-implant			
	TaurusOne®  NMPA Approval Internally Developed	TaurusElite®  NMPA Approval Internally Developed	TaurusMax® Completed Patient Enrollment of Registration Clinical Trial	TaurusNXT®  Completed Patient Enrollment of Multi-center Registration Clinical Trial Internally Developed	TaurusApex® Animal Studies Internally Developed	TaurusWave® Research Clinical Trial Internally Developed	
Mitral Valve	Replacement	Coaptation Augmentation	TEER				
	HighLife® (Transseptal)  Registration Clinical Trial  HighLife SAS	Sutra Animal Studies  Sutra	GeminiOne® Completed Patient Enrollment of Multi-center Registration Clinical Trial Internally Developed				6 Registered Products
Tricuspid Valve	Replacement	TEER		Platform Technology	Lithotripsy Valvuloplasty	Non-glutaraldehyde Crosslinked Dry-tissue	Polymeric Trileaflet
	MonarQ™ Compassionate Use  inQB8	GeminiOne® Clinical Trial Preparation Internally Developed			TaurusWave® Research Clinical Trial Internally Developed	TaurusNXT® Completed Patient Enrollment of Multi-center Registration Clinical Trial Internally Developed	TaurusApex® Animal Studies Internally Developed

Note: (1) Data as of June 16, 2024. (2) The above pipeline lists the Company's core products only and does not include procedural accessories and some iterations.

 Overseas R&D Partner
  Achieved Breakthrough in Clinical Trial from January 1, 2023 to the present
  Accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA.

TaurusTrio™ (In-licensed Trilogy™ THV System) for Aortic Regurgitation

Clinical data of US pivotal trial were published at Lancet

The ALIGN AR Trial

- Multicenter
 - Non-blinded
 - Single Arm Evaluation
- of Patients with Symptomatic
≥3+ Aortic Regurgitation at High Risk
for SAVR
- Enrolled 180 patients in total

Outcome


95.0% technical success

96.7% device success

92.8% procedure success

26.7% Primary Safety Endpoint at 30 Days

$P_{non-inferiority} < 0.0001$




Non-inferiority criteria met for primary safety endpoint

Variable	% (n)
All Cause Mortality	2.2% (4)
Cardiovascular Mortality	2.2% (4)
Any Stroke	2.2% (4)
Disabling Stroke	1.1% (2)
Nondisabling Stroke	1.1% (2)
Major/Life Threatening Bleeding	4.4% (8)
Major Vascular Complication	3.9% (7)
Acute Kidney Injury Stage 2 or 3 or Dialysis (7 Days)	1.1% (2)
Surgery / interventional Related to the Device	2.8% (5)
New Pacemaker Implantation	24.0% (36)
Pre-existing PPM	16.7% (30)
≥ Moderate Paravalvular Regurgitation	0.6% (1)
Total	26.7% (48)

7.8% Primary Efficacy Endpoint at 1 Year

$P_{non-inferiority} < 0.0001$



Non-inferiority criteria met for primary efficacy endpoint

LV Remodeling



TaurusTrio™ (In-licensed Trilogy™ THV System) for Aortic Regurgitation

Product design indicated for AR



CE Mark



FDA Breakthrough
Device Designation



■ Self-Expanding Nitinol Frame

■ Porcine Pericardial Tissue

■ JenaValve Patented Locator Technology

■ Sealing Ring

JenaValve Proprietary Locator Technology

- Ensures accurate and secure anatomical placement and alignment of the valve
- Mitigates risk of valve embolization and a need for a second valve to be implanted
- Improves valve durability

Designed to Facilitate Coronary Access

- Supra-annular design maximizes hemodynamics and provides ability to treat patients with low coronaries
- Large cell openings facilitate future access and provide clearance for low coronaries.
- 24 diamond-shaped cells provide annular conformability and sealing

Designed for Transfemoral Delivery System

- Deflector allows for accurate and precise placement of locators over cusps
- Controller mechanism to fine-tune position
- Custom 85cm introducer sheath protects aortic arch and is 18F equivalent

Designed to Maximize Hemodynamic Flow

- Supra-annular design maximizes hemodynamics compared with Sapien 3 and CoreValve
- JenaValve - All Sizes¹
Effective orifice area is 2.64cm²
Gradient across valve is 4.72mmHg

TaurusTrio™ (In-licensed Trilogy™ THV System) for Aortic Regurgitation


Project timeline



January 2022

Hong Kong

The first commercial
implant in Hong Kong



May 2023

Mainland China

Technology transfer
in mainland China

Multi-center
registration clinical
trial initiated in
Mainland China

Completed Patient Enrollment
of the Multi-center
Registration Clinical Trial

NMPA Approval



April 2023

July 2023

6 months

January 2024

Late 2025 - Early 2026

Contents

01

Business
Highlights

02

Transcatheter
Valve
Therapeutic
Business
Review

03

**Neuro
interventional
Business
Review**

04

Financial
Review

05


Appendix

Financial Overview | NI Business

Revenue growth exceeded expectation and segment loss narrowed by 98.8%.


Revenue

Million RMB




Adjusted Gross Profit and Gross Margin

Million RMB




Expenses

Million RMB



Segment Losses

Million RMB



Comprehensive and Balanced Portfolio

78% ↑
Revenue grew yoy


1:1:1 
Balanced Revenue Composition

Near 20% 
Contributed by new products⁽¹⁾



Hemorrhagic + 44.9% Million RMB




Ischemic + 117.3%



Vascular Access + 84.6%




2023



2022

Sales & Marketing Team HC



Distribution network covers **2,200** hospitals
across **31** provinces nationwide.

Note: (1) New products include Syphonet® Stent Retriever, Fastunnel® Delivery Balloon Dilation Catheter, Tethys AS® Aspiration Catheter, DCwire™ Micro Guidewire and Fluxcap® Balloon Guide Catheter.

Market Opportunities in the NI Business

Enhanced bottom line strength

The performance of domestic products is not inferior to imported products.

Systematic upstream market understanding, product development capability.

Operational capability

Cost control capability

Internal factors

Opportunities for Domestic Neurointerventional Companies

External factors

Launch of new products

Five products contributed nearly 20% of NI business's revenue in total.

Syphonet[®] Stent Retriever

Fastunnel[®] Delivery Balloon Dilatation Catheter

Tethys AS[®] Aspiration Catheter

DCwire[™] Micro Guidewire

Fluxcap[®] Balloon Guide Catheter

Innovations for technique

- JAMA
- ANSWER
- Zero Exchange
- BASIS
- REOPENS

- COSIS
- TRUST
- REST
- ATTACH
- TRANSFER

2021-2023 Coil Market Share: Domestic Products vs. Imported Products⁽¹⁾

Year	Domestic Products	Imported Products
2021	20%	80%
2022	27%	73%
2023	40%	60%

2021-2023 Coil Market Share for Achieva⁽¹⁾

Year	Market Share
2021	5%
2022	6%
2023	10%

VBPs accelerates domestic substitution, leading to an increase in the market share of domestic head companies.

Source: (1) Management's Analysis

VBP Policies Update

Relying on a rich product portfolio to embrace VBPs and capture market share

VBP for coils

- ✓ **won bids of VBPs** in Jiangsu, July 2022
- ✓ **won bids of VBPs** in Fujian, August 2022
- ✓ **won bids of VBPs** in Anhui, December 2022
- ✓ **won bids** in 21-province alliance VBP led by Jilin
 - ◆ (*Coils of Achieva ranked No.1 in total demand in domestic companies, and Jasper Detachable Coil were selected as one of the top three in Group A.)*
- ✓ **won bids** in Beijing DRG payment and VBP, September 2023
- ✓ **won bids of VBPs** in Guangdong, December 2023
 - ◆ (*Achieva coils win all bids: demand in the domestic weight ranked first, in the whole market ranked third, only after Medtronic, Stryker*)
 - The number of hospital admissions has increased dramatically through VBPs.
 - Sales volume of Achieva coil products increased by 94% in 2023.

- ✓ Delivery Balloon Dilatation Catheter **won bids exclusively**
 - ◆ Single-listed in the VBP Policies and won bids exclusively, market coverage of nearly 100%, revenue increased significantly.
- ✓ Intermediate Catheter、Distal Access Guide Catheter (DA)、Guide Catheter **won bids**
 - ◆ Market share of intermediate guide catheter sales reached 25%+, ranked NO.1.

VBP Policy in Henan Provincial Public Medical Institutions

The 9th round of VBP in Jiangsu Province

- ✓ Delivery Balloon Dilatation Catheter **won bids** exclusively
 - ◆ Single-listed in the VBP and won bids exclusively, market coverage of nearly 50% from 0
- ✓ Ballon Dilatation Catheter **won bids** in group B
 - ◆ First offer ranked in the top 50% from low to high to qualify for residual volume allocation, with a significant increase in the number of hospitals coverage
- ✓ Intermediate Catheter **won bids** in group B
 - ◆ First offer ranked in the top 50% from low to high to qualify for residual volume allocation, with a significant increase in the number of hospitals coverage
- ✓ Microcatheter **won bids** in group B
 - ◆ Significant increase in the number of hospital coverage

- ✓ Catheter **win bids**

VBP
Policies

VBP in Beijing-Tianjin-Hebei "3+N" Alliance

Innovative Techniques

We continued to strengthen our partnership with doctors in developing innovative procedure techniques.

Technique	Application	Product Mix
JAMA	Distal intracranial aneurysm or arteriovenous malformation	Jasper® Detachable Coil Jasper® SS Detachable Coil
ANSWER	Aneurysm embolism combined with intracranial artery stenosis	Jasper® Detachable Coil Jasper® SS Detachable Coil Fastunnel® Delivery Balloon Dilatation Catheter Tethys® Intermediate Catheter
Zero Exchange	Intracranial atherosclerosis	Fastunnel® Delivery Balloon Dilatation Catheter NeuroStellar® Intracranial Stent ⁽¹⁾
BASIS	Intracranial atherosclerosis-related large vascular occlusion	SacSpeed® Balloon Dilatation Catheter Syphonet® Stent Retriever
REOPENS	Intracranial and extracranial long-segmental, non-acute occlusion	
COSIS	Chronic occlusion of internal carotid artery	Syphonet® Stent Retriever
TRUST	Trans-radial access	Tethys® Intermediate Catheter
REST		
ATTACH		
TRANSFER		

¥ 14.4m ↑

Fastunnel®

Revenue growth

Formally launched in Feb 2023

↑ 339%

Syphonet®

Revenue grew YoY

88% ↑

























Tethys®

Revenue grew YoY

Note: (1) We are preparing for submitting the registration application of this product to the NMPA.

Pipeline Update

A well commercialized portfolio covering hemorrhagic, ischemic and vascular access markets.

	Pre-clinical, Clinical and Registration Stage				Launched					
Hemorrhagic	 Intracranial Adjunctive Stent	 Jasper® Detachable Coil II			 Jasper® Detachable Coil	 Presgo® Detachable Coil	 Jasper® SS Detachable Coil	 NRcoil™ Detachable Coil		
Ischemic	 SacSpeed® Ballon Dilatation Catheter II	 Fastunnel® Delivery Balloon Dilatation Catheter II	 Tethys AS® Aspiration Catheter II	 NeuroStellar® Intracranial Stent	 SacSpeed® Ballon Dilatation Catheter	 Syphonet® Stent Retriever	 Tethys AS® Aspiration Catheter	 Fluxcap® Balloon Guide Catheter	 Fastunnel® Delivery Balloon Dilatation Catheter	
Vascular Access	 Delivery Catheter (Large Lumen)	 Radial Artery Support Catheter	 Tethys® Intermediate Catheter II		 Presgo® Microcatheter	 Presgo® Micro Guidewire	 Heralder® Guide Catheter	 Tethys® Intermediate Catheter	 Heralder® DA Distal Access Guide Catheter	 DCwire™ Micro Guidewire

Note: Above status is as March 31, 2024.

 Newly registered product in 2023

Content

01

Business
Highlights

02

Transcatheter
Valve
Therapeutic
Business
Review

03

Neuro
interventional
Business
Review

04

Financial
Review

05


Appendix

Financial Summary

Revenue

Million RMB


■ TVT Business
■ NI Business



Gross Profit and Gross Margin

Million RMB


■ Gross Profit of TVT Business
■ Adjusted Gross Profit of NI Business⁽¹⁾
○ Adjusted Gross Margin⁽¹⁾



Expenses


Million RMB

■ TVT Business
■ NI Business



Net Losses

Million RMB




Note: (1) Adjusted gross margin and gross profit within this presentation refer to the gross margin and gross profit calculated after adding back the Purchase Price Allocation ("PPA"), unless otherwise stated. PPA is a non-cash item, arising from the acquisition of Achieva Medical in 2019, which means the allocation of the cost of a business combination under non-same control among the identifiable assets, liabilities and contingent liabilities, unless otherwise stated.

Expense Breakdown

R&D Expenses

Million RMB


- TVT Business
- NI Business
- One-time BD Expenses⁽¹⁾



S&D Expenses

Million RMB

- TVT Business
- NI Business



Admin Expenses

Million RMB


- TVT Business
- NI Business




Note: (1) One-time BD Expenses within this presentation refers to one-time, non-recurring BD expenses, unless otherwise stated.

Operational Efficiency


Gross Margin




S&D Expense Ratio




Administrative Expense Ratio




Adjusted Gross Margin



S&D Expense Ratio



Administrative Expense Ratio




■ TVT Business

■ NI Business

S&D Expenses and S&D Expense Ratio


TVT Revenue, S&D Expenses & S&D Expense Ratio

Million RMB



NI Revenue, S&D Expenses & S&D Expense Ratio

Million RMB



TVT Revenue & S&D Expense Per Sales Person

Million RMB



NI Revenue & S&D Expense Per Sales Person

Million RMB




Sufficient Liquidity to Support Future Development

The maximum amount of remaining one-time BD payments is no more than RMB300M

Net Cash Used in Operating Activities


Million RMB

- ▨ One-time BD Payments
- Net cash Used in Operating Activities excluding One-time BD Payments



Cash, Cash Equivalents and Term Deposits

Million RMB



Note: (1) Total amount based on full realization of all milestone payment obligations, i.e., the maximum possible remaining amount.

TVT Business

Revenue constantly grew at high-double digits and gross profit margin maintained the highest among peers.


Revenue

Million RMB




Gross Profit and Gross Margin

Million RMB




Expenses

Million RMB



Segment Losses

Million RMB




TVT Business

Expense ratios improved significantly as the emergence of economic scales.


R&D Expenses

Million RMB




S&D Expenses

Million RMB



Administrative Expenses

Million RMB



■ Core Products⁽¹⁾ ■ Adjusted Advanced Tech Products⁽²⁾

■ One-time BD Expenses

● R&D Expenses (Excluding One-time BD Expenses) as a % of Revenue

● % of Revenue

● % of Revenue

Note: (1) Core products and advanced tech products within this presentation refer to two groups of products in this presentation unless otherwise stated. Please refer to product classification as presented in Appendix;


(2) Adjusted advanced tech products within the presentation refer to adjusted R&D expenses of advance tech products excluding the one-time BD expenses of these products unless otherwise stated..

NI Business

Revenue growth exceeded expectation and segment loss narrowed by 98.8%.


Revenue

Million RMB




Adjusted Gross Profit and Gross Margin

Million RMB




Expenses

Million RMB



Segment Losses

Million RMB




NI Business

Expense ratios dropped significantly due to effective cost control measures and rapid revenue growth.

R&D Expenses


Million RMB



■ Core products ■ Advanced tech products ○ % of Revenue

S&D Expenses


Million RMB



○ % of Revenue

Administrative Expenses

Million RMB




○ % of Revenue

NI Business

Channel strategy remained prudent while platforms were utilized to respond to orders more efficiently.


Revenue

Million RMB




End User Usage⁽¹⁾

Million RMB




Average Channel Inventory⁽²⁾

Million RMB



End User Usage / Average Channel Inventory

Times



Note: (1) End User Usage = Beginning Inventory – Ending Inventory + Current Delivery; (2) Average Inventory = (Inventory at the Beginning of the Period + Inventory at the end of the Period) / 2.

Content

01

Business
Highlights

02

Transcatheter
Valve
Therapeutic
Business
Review

03

Neuro
interventional
Business
Review

04

Financial
Review

05

Appendix

Product Classification

Core Products

TaurusOne® TAVR System	Jasper® Detachable Coil
TaurusElite® Retrievable TAVR System	Presgo® Detachable Coil
TaurusNXT® <i>Non-glutaraldehyde Crosslinked Dry-tissue</i> TAVR System	Jasper® SS Detachable Coil
	NRcoil™ Detachable Coil
TaurusAtlas® Transfemoral Balloon Catheter	SacSpeed® Balloon Dilatation Catheter
TaurusNavi® Introducer Sheath	Tethys AS® Aspiration Catheter
TaurusExplora® Pre-shaped Guidewire	Syphonet® Stent Retriever
	Fastunnel® Delivery Balloon Dilation Catheter
	Fluxcap® Balloon Guide Catheter
	Presgo® Microcatheter
	Presgo® Micro Guidewire
	DCwire™ Micro Guidewire
	Heralder® Guide Catheter
	Jasper® Power Supply
	Tethys® Intermediate Catheter
	Heralder® DA Distal Access Guide Catheter

■ TVT Business

■ NI Business

Advanced Tech Products

TaurusWave® Lithotripsy Valvuloplasty System
TaurusApex® Polymeric Trileaflet TAVR System
Trilogy™ TAVR System (<i>Licensed-in</i>)
TaurusTrio™ TAVR System (<i>Licensed-in Trilogy™ TAVR System</i>)
HighLife® TSMVR System (<i>Licensed-in</i>)
Sutra TMV Coaptation Augmentation System
GeminiOne® TEER System
MonarQ TTVR System
NeuroStellar® Intracranial Stent
CereStellar™ Intracranial Adjunctive Stent
Jasper® Detachable Coil II
Fastunnel® Delivery Balloon Dilation Catheter II
SacSpeed® Balloon Dilatation Catheter II
Tethys® Intermediate Catheter II
Radial Artery Support Catheter
Delivery Catheter (Large Lumen)
Tethys AS® Aspiration Catheter II

Neurointerventional Procedure Techniques

Technique	Detail	Application	Product Mix
JAMA	Using J Asper/ J AsperSS coils with M Arathon micro catheter to treat distal aneurysms and arteriovenous malformation	Distal intracranial aneurysm or arteriovenous malformation	Jasper® Detachable Coil Jasper® SS Detachable Coil
ANSWER	A Neury S m W ith stenosis treatment using fastun n E I delive R ing balloon dilatation catheter	Aneurysm embolism combined with intracranial artery stenosis	Jasper® Detachable Coil Jasper® SS Detachable Coil Fastunnel® Delivery Balloon Dilatation Catheter Tethys® Intermediate Catheter
Zero Exchange	N/A	Intracranial atherosclerosis	Fastunnel® Delivery Balloon Dilatation Catheter NeuroStellar® Intracranial Stent
BASIS	B alloon A ngiopl a S t y with the d istal protection of S tent retriever	Intracranial atherosclerosis-related large vascular occlusion	SacSpeed® Balloon Dilatation Catheter Syphonet® Stent Retriever
REOPENS	R Ecanalization of intracranial and extracranial long-segmental, non-acute O cclosure with the distal P rot E ctio N of S yphonet	Intracranial and extracranial long-segmental, non-acute occlusion	
COSIS	C hronic artery O cc l u S ion recanalization with the I ntracranial protection of S tent Retriever	Chronic occlusion of internal carotid artery	Syphonet® Stent Retriever
TRUST	T rans- R adial coaxial catheter technique U sing a short sheath, S immons catheter and T ethys intermediate catheter	Trans-radial access	
REST	Trans- R adial E stablish S imple access technique with T ethys intermediate catheter		Tethys® Intermediate Catheter
ATTACH	A T rans-radial technique using looping T ethys intermediate catheter with two lo A C H guide wires		
TRANSFER	Re T rieving A protection N device with d istal access catheter along the F easible st E nt delivery system by trans- R adial approach		Heralder® DA Distal Access Guide Catheter

Thank you!

Contact us

Investor Relations | Peijia Medical Limited

Email: ir@peijiamedical.com

